These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38071724)

  • 1. One-Year Medication Treatment Patterns, Healthcare Resource Utilization, and Expenditures for Medicaid Patients with Schizophrenia Starting Oral Atypical Antipsychotic Medication.
    Richards K; Johnsrud M; Zacker C; Sasané R
    Adm Policy Ment Health; 2024 Mar; 51(2):207-216. PubMed ID: 38071724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Persistence with Oral Atypical Antipsychotic Medications and Hospital and Emergency Department Utilization in Medicaid Patients with Schizophrenia.
    Richards K; Johnsrud M; Zacker C; Sasané R
    Patient Prefer Adherence; 2024; 18():177-185. PubMed ID: 38259956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
    Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
    Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.
    Hansen RA; Maciejewski M; Yu-Isenberg K; Farley JF
    Psychiatr Serv; 2012 Sep; 63(9):920-8. PubMed ID: 22706887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics.
    Pilon D; Patel C; Lafeuille MH; Zhdanava M; Lin D; Côté-Sergent A; Rossi C; Lefebvre P; Joshi K
    J Manag Care Spec Pharm; 2021 Jul; 27(7):904-914. PubMed ID: 34185557
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
    Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
    J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Medication Nonadherence and Comorbidity on Health Resource Utilization in Schizophrenia.
    Desai R; Nayak R
    J Manag Care Spec Pharm; 2019 Jan; 25(1):37-46. PubMed ID: 30589635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
    Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
    J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia.
    MacEwan JP; Forma FM; Shafrin J; Hatch A; Lakdawalla DN; Lindenmayer JP
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1349-1361. PubMed ID: 27783548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
    Gilmer TP; Dolder CR; Lacro JP; Folsom DP; Lindamer L; Garcia P; Jeste DV
    Am J Psychiatry; 2004 Apr; 161(4):692-9. PubMed ID: 15056516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the relationship between quality measure adherence definitions and economic outcomes in commercial health plans: a retrospective diabetes cohort study.
    Chinthammit C; Axon DR; Mollon L; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
    J Manag Care Spec Pharm; 2021 Jan; 27(1):64-72. PubMed ID: 33377445
    [No Abstract]   [Full Text] [Related]  

  • 15. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
    Joshi K; Pan X; Wang R; Yang E; Benson C
    Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
    Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
    BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
    Offord S; Lin J; Mirski D; Wong B
    Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia.
    Shafrin J; Schwartz TT; Lakdawalla DN; Forma FM
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1285-1291. PubMed ID: 27783545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization.
    Markowitz M; Karve S; Panish J; Candrilli SD; Alphs L
    BMC Psychiatry; 2013 Oct; 13():246. PubMed ID: 24094241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
    Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
    Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.